Introduction
============

As specific bloodsucking ectoparasites, leeches have to penetrate hosts' body surface and suppress the reactions of hosts to injuries, such as swelling, pain, and inflammation to remain undetected and successfully get blood meal, suggesting that anesthetic agents may delivered during the blood-sucking process. Furthermore, they have to overcome hemostatic and vasoconstriction reactions in hosts to ensure a steady and sustained blood flow to the feeding site. Leeches inject saliva into hosts to counteract the reactions of hosts.

With many clinically challenges, pain affects millions of individuals worldwide and remains poorly understood. VGSCs (voltage-gated sodium channels) are essential for pain perception because they play a critical role in the generation and propagation of action potentials in excitable cells, including neurons, muscle cells, and cardiomyocytes. Nine subtypes (Na~V~1.1--1.9) of VGSCs have been identified in mammals. VGSCs have been broadly classified as TTX-S (TTX-sensitive) and TTX-R (TTX-resistant) by their sensitivities to tetrodotoxin (TTX). The majority of DRG (dorsal root ganglion) neurons express at least six Na~V~ subtypes ([@B9]; [@B40]): Na~V~1.1, Na~V~1.6, Na~V~1.7, Na~V~1.8, Na~V~1.9, and Nax ([@B13]). The TTX-S Na~V~ current produced by Na~V~1.1, Na~V~1.6 and Na~V~1.7 is fast-inactive. Whereas, Na~V~1.8 and Na~V~1.9 produce the slow-inactivating TTX-R current ([@B1]).

Different sodium channel subtypes have specific distributions and functions. Sodium channel Na~V~1.8 is mainly expressed in peripheral neurons, in particular within retinal amacrine and ganglion cells ([@B29]), small and medium-sized DRG neurons, and nociceptive afferent fibers ([@B7]; [@B37]); Na~V~1.9 is expressed more widely. It is found in the hippocampus, cortex ([@B8]), photoreceptors and Müller glia, small diameter DRG, trigeminal ganglia, and the intrinsic sensory neurons of the gut ([@B15]; [@B35]; [@B31]).

Compared with other TTX-S channels, Na~V~1.8 is known to produce a slow-inactivating TTX-R current and is characterized by significantly depolarized activation and inactivation. Na~V~1.9 exhibits unique biophysical properties that include a hyperpolarized voltage-dependent activation and inactivation curves that overlap to produce a large 'window current' and very slow activation and inactivation kinetics ([@B11]). Studies in knockout animals have clearly established a role of Na~V~1.8 in pain ([@B1]; [@B46]). Furthermore, gain-of-function mutations of Na~V~1.8 have been found in human subjects with painful neuropathies. These mutations in Na~V~1.8 channel markedly alter the excitability of DRG neurons ([@B14]; [@B21]; [@B16]). Similarly, several monogenic human pain disorders are linked to altered Na~V~1.9 channel function. For example, some mutations in SCN11A (Na~V~1.9) resulted in a gain of function at the channel level and were associated with increased pain ([@B45]; [@B19], [@B20]), whereas in other study, a mutation (L811P) at the Na~V~1.9 channel resulted in an inability to experience pain ([@B27]). In addition, studies using prostaglandin E2, protein kinase C, intracellular GTPγS (hydrolysis-resistant GTP analog), or G proteins have demonstrated a link between inflammatory pathways and Na~V~1.9 channel ([@B6]; [@B36]; [@B5]; [@B30]; [@B34]). Na~V~1.9 is important for the perception of pain in response to cold. Cold pain sensation was greatly reduced in neurons from Na~V~1.9 knockout mice ([@B26]; [@B28]). These observations indicate that Na~V~1.8/9 represents a high-valued target for development of analgesics.

Blood-sucking leeches have been used for medical purposes in humans for more than 2000 years. Leeches have been approved as medicinal materials or medical device in many countries ([@B22]). As a traditional anti-thrombosis medicinal material, leeches have been used in China for over 1000 years. The FDA has approved leeches as a medical device for plastic and reconstructive surgery in July 2004 ([@B32]). Recently, leech therapy has been approved as legal therapeutic intervention in Europe. Especially, extensive attention has been paid for medicinal leech therapy in pain syndromes, such as osteoarthritis, epicondylitis, vertebrogenic pain syndromes/lower back pain, hematoma/swelling/edema/contusion/distortion, varicose veins/leg ulcer/phlebitis/thrombophlebitis, and cancer pain ([@B25]). Analgesic effect of leech therapy has been approved in many clinic trials. The analgesic effect from leech therapy is rapid, effective, and long-lasting in many conditions ([@B38]). However, no specific substance with analgesic function has been reported from leech yet. In this study, we identified a novel group of peptides targeting Na~V~1.8 and Na~V~1.9 to produce analgesic effect for the first time.

Materials and Methods {#s1}
=====================

Collection of Saliva Sample From *H. sylvestris*
------------------------------------------------

*Haemadipsa sylvestris* (total weight 500 g) was collected from jungles in Yunnan, China. Saliva sample was collected as described below. Living leeches were frozen quickly in liquid nitrogen. Leech saliva located in the subcutaneous of pharynx was separated, collected and triturated by grinder (Joyoung, China) at low temperature. Triturated saliva sample was dissolved in deionized water, and immediately centrifuged to remove debris. The supernatant \[crude extract of saliva (CES)\] was lyophilized and kept at -20°C till use. All of the experimental protocols using animals were approved by the Animal Care and Use Committee at Kunming Institute of Zoology, Chinese Academy of Sciences (SYDW-2013018).

Peptide Purification
--------------------

The CES was applied to a Sephadex G-50 gel filtration column (GE Healthcare, 20--100 μm, 2.6 cm × 100 cm) which was equilibrated with Tris-HCl buffer (50 mM Tris-HCl, pH 8.9). Sample fractionation was performed by eluting the column using Tris-HCl buffer. Each eluted fraction with a volume of 3.0 ml was collected every 10 min and the absorbance of the eluate was measured at 215 and 280 nm. The effects of eluted fractions (desalted) on VGSCs were assayed using whole-cell patch clamp techniques as described below. The fractions containing VGSCs-inhibiting activity were pooled, lyophilized, and resuspended in 10 ml of the Tris-HCl buffer. The fractions were further purified by using RP-HPLC with C18 column (SunFire^TM^ Prep C~18~, 5 μm, 250 mm × 10 mm, Waters) by using acetonitrile containing 0.1% trifluoroacetic acid (TFA) as elution solvent. The absorbance at 215 and 280 nm was monitored by UV detector (Waters 2489).

Determination of Amino Acid Sequence
------------------------------------

Edman degradation was used to analyze the amino sequence of purified peptides by pulsed liquid-phase sequencer (Applied Biosystems, model 491). Molecular weight was determined by MALDI-TOF-MS (Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, autoflex^TM^ speed, Bruker) by using positive reflector mode and reported as the monoisotopic \[M + H\]^+^ ions, with ± 0.001% accuracy of mass determinations.

Construction and Screening of *H. sylvestris* Salivary Gland cDNA Library
-------------------------------------------------------------------------

Total RNA was extracted using TRIzol Reagent (Invitrogen, United States) from salivary gland (100 mg) of *H. sylvestris* according to our previous methods ([@B3]). An Oligotex mRNA Mini kit (Qiagen, Duesseldorf, Germany) was used to extract mRNA. cDNA library was constructed by using a Creator SMART^TM^ cDNA Library Construction Kit (Clontech, Palo Alto, CA, United States) following manufacturer's instructions, and finally a library of about 2 × 10^6^ independent colonies was produced.

Primers HS1 (5′-GGCAATATTCAAGTCGAAGCTTGC-3′) designed according to the homologous sequences determined by transcriptome sequencing, and CDS III (5′-ATTCTAGAGGCCGAGGCGGCCGACATG-3′) were used for 3′ end DNA amplification. Primers HS2 (5′-GAAACATTTTAATTTTTAGAGGTTCATCC-3′) designed according to transcriptome data, and CDSIII were used for 5′ end DNA amplification. The PCRs were performed by using Advantage polymerase (Clontech, Palo Alto, CA, United States) as follows: 5 min at 95°C followed by 35 cycles of 10 s at 95°C, 30 s at 50°C, 40 s at 72°C, and last 10 min at 72°C. The PCR products were purified by DNA Gel Extraction Kit (Tiangen, China) and ligated into pMD19-T vector (TaKaRa Biotechnology Dalian, Co., Ltd., China) following manufacturer's instructions. DNA sequencing was performed on an Applied Biosystems DNA sequencer (ABI PRISM377).

Intra-molecular Disulfide Bridge Analysis
-----------------------------------------

After incubation in 6 M guanidine solution (pH 3.0) at 37°C for 30 min, native peptide (3 mg) was partially reduced with Tris (2-carboxyethyl) phosphine hydrochloride (0.1 M) at 37°C for 40 min in 0.1 M citrate buffer solution (pH 3.0). The products were purified and lyophilized. The reduced half-cysteines in the peptide were alkylated with 0.5 M iodoacetamide in 0.5 M *N*-methyl morpholine solution (pH 8.3) at 25°C for 30 s. Amino acid sequence of reduced peptide was analyzed by Edman degradation ([@B41]).

Structure Prediction and Modeling
---------------------------------

The structure of HSTX-I was modeled (Supplementary Data Sheet [2](#SM2){ref-type="supplementary-material"}) by homology modeling using 3BT4 (PDB ID) as a template. The suitable template for modeling was selected by BLAST result (Supplementary Figure [6](#SM1){ref-type="supplementary-material"}) and disulfide bond assignment (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}). After suitable template is selected, the PDB file is parsed to extract its sequence. The amino acids of the template are replaced with that of HSTX-I to achieve template sequence alignment. Minimization (QM-MM) protocol was used to minimize the energy of HSTX-I sidechains through geometry optimization using the hybrid delocalized internal coordinate (HDLC) optimizer. The QM region of atoms is treated by a quantum calculation using the DMol^3^ server and the rest MM is handled by the CHARMm forcefield.

The structure was predicted and modeled using the Discovery Studio (3.1, BIOVIA, San Diego, CA, United States) software and following the data from Edman degradation.

Tissue Distribution of the Analgesic Peptide by qPCR
----------------------------------------------------

RNA was extracted from head, body, and tail of *H. sylvestris*, respectively. The expression pattern analyzed by qPCR was repeated three times. HSTX-I and GAPDH primers were designed using IDT Primerquest tools^[1](#fn01){ref-type="fn"}^ as listed in Supplementary Table [1](#SM1){ref-type="supplementary-material"}. SYBR Green PCR kit (Applied Biosystems) was used to perform qPCR. The qPCR procedures were as follows: 5 min of denaturation at 95°C, followed by 40 cycles of amplification with 5 s of denaturation at 94°C, 20 s of annealing according to the melting temperatures provided in Supplementary Table [1](#SM1){ref-type="supplementary-material"} and 15 s of extension at 72°C. The fluorescence data were collected at the end of each cycle. After a final extension at 72°C for 10 min, the specificity of the amplified product was evaluated by melting curve.

Voltage-Clamp and Current-Clamp Recordings
------------------------------------------

Animal studies followed a protocol (SYDW-2013018) approved by the Animal Care and Use Committee at Kunming Institute of Zoology, Chinese Academy of Sciences. For patch clamp recording, DRG neurons were isolated, as previously reported ([@B44]). Briefly, rat DRG neurons were harvested and incubated at 37°C for acute dissociation in enzymatic solution \[DMEM medium (Corning, NY, United States) with 0.3% collagenase (Sigma, St. Louis, MO, United States) and 0.7% trypsin (Sigma, St. Louis, MO, United States)\]. After 20 min, the enzymatic solution was replaced by DMEM complete growth medium with 0.3% trypsin inhibitor (Sigma, St. Louis, MO, United States) and maintained in short-term primary culture. All cells were used within 12 h of isolation.

Ca^2+^, K^+^, and Na^+^ currents were recorded from cells using the whole-cell patch clamp technique performed as previously described ([@B23]; [@B26]; [@B28]; [@B42]). The P/4 protocol was used to subtract linear capacitive and leakage currents. For sodium channel current recordings on DRG neurons, the bath solution contained the following (in mM): 30 NaCl, 25 [D]{.smallcaps}-glucose, 1 MgCl~2~, 1.8 CaCl~2~, 90 TEA-Cl, 5 CsCl, and 5 HEPES at pH 7.4; the pipettes internal solution contained (in mM): 135 CsF, 10 NaCl, and 5 HEPES at pH 7.4. Adding 300 nM TTX (tetrodotoxin) and neurons diameter (\<25 μm) were used for discriminating TTX-R from TTX-S Na~V~ channels. Cells were activated by a 100-ms step depolarization to -10 mV from a holding potential of -80 mV for Na~V~ currents. For potassium channel, the external solution was (in mM): 130 NaCl, 5 KOH, 12 [D]{.smallcaps}-glucose, 2 CaCl~2~, 2 MgCl~2~, and 10 HEPES, pH 7.2; pipettes were filled with a solution containing (in mM): 120 KF, 20 NMDG (*N*-methyl-[D]{.smallcaps}-glucamine), 11 EGTA, 2 Na-ATP, 0.5 GTP, and 10 HEPES, pH adjusted to 7.2 with KOH. Cells were evoked by a 500-ms depolarizing potential of +10 mV from a holding potential of -80 mV to record K~V~ currents. For calcium current recording, the pipette internal solution contained the following (in mM): 110 CsCl, 5 MgCl~2~, 10 EGTA, 25 HEPES, and 2 Mg-ATP, pH adjusted to 7.2 with CsOH; the bath solution contained the following (in mM): 125 TEA-Cl, 10 BaCl~2~, 5 HEPES, 5 [D]{.smallcaps}-glucose, pH adjusted to 7.3 with CsOH. Cells were activated by a 150-ms step depolarization to +10 mV from a holding potential of -90 mV for Ca~V~ currents. ∼1 μM TTX was added in potassium and calcium bath solution to block Na~V~ current. For Na~V~1.8 channel voltage-clamp recording, DRG neurons (diameter \< 25 μm with 300 nM TTX) were held at -70 mV to inactivate Na~V~1.9 channels. Furthermore, neurons with potential contamination of Na~V~1.9 current were excluded. For Na~V~1.9 channels voltage-clamp recording, Na~V~1.8-null mouse DRG neurons (diameter \< 20 μm with 300 nM TTX) were activated by a 100-ms step depolarization to -40 mV from a holding potential of -110 mV for Na~V~1.9 currents. The bath and pipettes solution for Na~V~1.8 and Na~V~1.9 contained the following (in mM): 150 NaCl, 2 KCl, 5 [D]{.smallcaps}-glucose, 1 MgCl~2~, 1.5 CaCl~2~, and 10 HEPES at pH 7.3; the pipettes internal solution contained (in mM): 105 CsF, 35 NaCl, 10 HEPES, 10 MgCl~2~, and 10 EGTA at pH 7.3.

Concentration-response curves were fitted using the following Variable slope model: Y = Bottom + (Top-Bottom)/(1+10^∧^((LogIC~50~-X)^∗^HillSlope)) where HillSlope is the steepness of the family of curves, Top and Bottom are the fraction of current resistant to inhibition at low toxin concentration and high toxin concentration, respectively. For current--voltage (I--V) relationships, cells were held at -70 mV (-110 mV for Na~V~1.9 channels) and depolarized to potentials from -80 mV (-100 mV for Na~V~1.9 channels) to +40 mV in 5 mV increments for 100 ms, and peak currents were recorded. Conductance--voltage (G--V) relationships were determined from peak current (I) versus voltage relationships as G = I/(V-V~rev~), where V was the test potential, and V~rev~ was the extrapolated reversal potential. Steady-state fast inactivation was achieved with a series of 500-ms prepulses -100 mV (-120 mV for Na~V~1.9) to +10 mV in 10 mV increments, and the remaining non-inactivated channels were activated by a 40-ms step depolarization to 0 mV (-40 mV for Na~V~1.9). Steady-state inactivation curves were fitted using the Boltzmann equation. The patch pipettes with DC resistances of 2--3 M were fabricated from borosilicate glass tubing (VWR micropipettes, 100 mL, VWR, Radnor, PA, United States) using a two-stage vertical microelectrode puller (PC-10, Narishige, Tokyo, Japan) and fire-polished by a heater (Narishige, Tokyo, Japan). Recordings were sampled at a rate of 50 kHz, and filtered at 3 kHz.

Before proceeding to current-clamp recordings, the same amplifier with the same configurations as voltage-clamp recordings was used. Pipette solution and bath solution was the same as previously described. The voltage threshold was determined by the first action potential elicited by a series of 1000 ms depolarizing current injections that increased in 50-pA increments. Cells with unstable (\>10% variation) resting membrane and action potential overshoot of \<40 mV were excluded for data collection.

All data recordings were performed at room temperature using an Axon Multiclamp 700B amplifier (Molecular Devices, Silicon Valley, CA, United States).

Anti-nociceptive Test
---------------------

To evaluate anti-nociceptive function of samples on mice (female, 18--22 g), several animal models including formalin-induced paw licking, abdominal writhing induced by acetic acid, and hot plate test were used according to previous methods ([@B43]). Morphine and saline were used as positive and negative control, respectively.

In formalin-induced paw licking model, mice were injected intraperitoneally with test sample dissolved in 100 μl of saline. Thirty minutes later, animals were injected with 20 μl of 1% (vol/vol) formalin at the subcutaneous tissue on plantar surface of right hind paw. Mice were then placed individually into open polyvinyl cages (20 cm × 40 cm × 15 cm). Times of licking the injected paw were recorded by digital video camera during phase I (0--5 min post-injection) and II (15--30 min post-injection).

In the model of abdominal writhing induced by acetic acid, after 30 min of intraperitoneal injection of test sample in one side of abdomen of mice, 100 μl of 1.5% (vol/vol) acetic acid was injected into the other side of abdomen. Mice were placed into open polyvinyl cages (20 cm × 40 cm × 15 cm) immediately, and nociceptive behaviors were counted cumulatively over a period of 30 min.

For hot plate test, mice (female) were placed on a hot plate (ZH-Z organ measurement system, China) with temperature maintained at 55 ± 0.5°C. The response time between placement of the mice on the plate and licking the paws or jumping was recorded as latency (in seconds). The latency was recorded at 0, 30, 60, 90, and 180 min after the intraperitoneal administration of test sample dissolved in 0.9% saline ([@B43]).

Data Analysis
-------------

Electrophysiological data were analyzed using program Clampfit 10.0 (Molecular Devices) and GraphPad Prism 6. Statistical significance was determined by paired Student's *t*-tests or ANOVA. Other experimental results are expressed as means ± SEM. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 are significantly different compared with the control.

Ethics and Biosecurity Statement
--------------------------------

All of the experimental protocols using animals were approved by the Animal Care and Use Committee at Kunming Institute of Zoology, Chinese Academy of Sciences (SYDW-2013018). All the researches involving biohazards, biological select agents, toxins, restricted reagents and venom were approved by the Biosafety Committee of Kunming Institute of Zoology, Chinese Academy of Sciences (KZR-2015047).

Results
=======

Purification of Peptide Possessed Activity to Inhibit VGSCs (Voltage-Gated Sodium Channels)
-------------------------------------------------------------------------------------------

As illustrated in Supplementary Figure [1A](#SM1){ref-type="supplementary-material"}, the extracts of the leech salivary glands were divided into six fractions by Sephadex G-50 gel filtration. Fraction III was found to inhibit TTX-R (tetrodotoxin-resistant) sodium channel currents and was purified further by a C~18~ RP-HPLC (reverse-phase high performance liquid chromatography) (Supplementary Figure [1B](#SM1){ref-type="supplementary-material"}). A peptide named HSTX-I, which contained activity to inhibit TTX-R sodium channel currents was purified.

Amino Acid Sequence of HSTX-I
-----------------------------

The complete amino sequence (ACKEYWECGAFLFCIEGICVPMI) of HSTX-I was determined by Automated Edman Degradation. The cDNA sequence encoding the precursor of HSTX-I was cloned from the cDNA library of *H. sylvestris* salivary gland (**Figure [1A](#F1){ref-type="fig"}**). The precursor is composed of 49 AA (amino acid) residues including a predicted 25-AA signal peptide, a mature HSTX-I and a glycine at the C-terminal, which provides a -NH~2~ for- C-terminal amidation like other neuropeptides or antimicrobial peptides ([@B18]; [@B10]).

![HSTX-I from *Haemadipsa sylvestris* saliva. **(A)** cDNA sequence encoding HSTX-I precursor. Mature peptide was determined by Edman sequencing (gray background). Asterisks indicate stop codon. **(B)** Sequence alignment of HSTX-I with its homologous sequences identified from cDNA library of *H. sylvestris* salivary glands. The conserved half-cysteines are highlighted by gray background. Asterisks indicate conserved residues. The mature peptide is underlined. The assignment of the disulfide bonds of HSTX-I is Cys2-Cys14 and Cys8-Cys19 which are indicated by red lines. **(C)** The secondary structure and disulfide bonds of HSTX-I are demonstrated by Discovery Studio. The disulfide bonds are linked in yellow line, the turn is shown in green, beta strands are shown in blue and random coils are shown in gray. **(D)** Tissue distribution of HSTX-I revealed by qPCR in *H. sylvestris*. Statistically significant differences compared with the head group (calculated using a two-tail Student's *t*-test) are indicated by ^∗∗∗^*P* \< 0.001.](fphar-09-00186-g001){#F1}

Ten homologous sequences of HSTX-I were also cloned from the cDNA library (**Figure [1B](#F1){ref-type="fig"}**). All of them share highly conserved cysteine motifs and signal sequence. BLAST search did not find any similarity to other known peptides or proteins, indicating these peptides are a novel peptide family. Eleven members of this peptide family are found in the cDNA library of the leech salivary glands, which confirms the diversity of the peptide family in this species.

The mature peptide contains four cysteines, which form two intra-molecular disulfide bonds, Cys2-Cys14 and Cys8-Cys19 (**Figures [1B,C](#F1){ref-type="fig"}** also see Supplementary Figure [2A](#SM1){ref-type="supplementary-material"}). Carboxypeptidase Y treatment did not release the C-terminal amino acid residue, indicating that the C-terminal residue in HSTX-I is amidated. MALDI-TOF mass spectrometry (Supplementary Figure [2B](#SM1){ref-type="supplementary-material"}) analysis gave an observed molecular mass of 2621.14 Da which is identical with the calculated molecular mass (2621.17 Da) of HSTX-I with two intra-molecular disulfide bridges and an amidated C-terminus.

The distribution of HSTX-I in leech was evaluated by qPCR (real-time quantitative PCR). The results showed that the expression level of HSTX-I in the head of leech was 2--3 times higher than those in body and tail (**Figure [1D](#F1){ref-type="fig"}**).

Effects of HSTX-I on Na~V~1.8/1.9 Channels
------------------------------------------

Because HSTX-I showed inhibitory effects on TTX-R sodium channels (see Supplementary Figure [4](#SM1){ref-type="supplementary-material"}) including Na~V~1.8 and Na~V~1.9, effects of HSTX-I on rNa~V~1.8 (rat Na~V~1.8) and mNa~V~1.9 (mouse Na~V~1.9) were investigated. As illustrated in **Figure [2](#F2){ref-type="fig"}**, HSTX-I reduced Na~V~1.8/1.9 currents with IC~50~ ∼2.44 ± 1.42 (**Figure [2C](#F2){ref-type="fig"}**) and 3.30 ± 2.48 (**Figure [2D](#F2){ref-type="fig"}**) μM, respectively. HSTX-I (3 μM) had no effect on G--V relationship and steady-state inactivation of rNa~V~1.8 (**Figure [2E](#F2){ref-type="fig"}**) channels. HSTX-I (3 μM) had no effect on steady-state inactivation of mNa~V~1.9 channels. In contrast, HSTX-I (3 μM) shifted steady-state activation to hyperpolarizability of ∼5 mV on mNa~V~1.9 (**Figure [2F](#F2){ref-type="fig"}**) channels.

![HSTX-I inhibited Na~V~1.8/1.9 channels (also see Supplementary Figure [5](#SM1){ref-type="supplementary-material"}). **(A)** Representative current traces of rNa~V~1.8 recorded from the rat small DRG neurons (\<25 μm) with 300 nM TTX at holding voltage of --70 mV. **(B)** Representative current traces of mNa~V~1.9, recorded from the Na~V~1.8-null mouse small DRG neurons (diameter \< 25 μm with 300 nM TTX) at holding potential of --110 mV. Control currents are shown in black and the inhibition of rNa~V~1.8 **(A)** and mNa~V~1.9 **(B)** by the indicated concentrations of HSTX-I are shown in red. **(C)** Concentration-response curves for the inhibition of rNa~V~1.8 by HSTX-I. Cells were activated by a 100-ms step depolarization to --10 mV from a holding potential of --70 mV for the IC~50~ of HSTX-I on rNa~V~1.8 channel. **(D)** Concentration-response curves for the inhibition of mNa~V~1.9 by HSTX-I. Cells were activated by a 100-ms step depolarization to --40 mV from a holding potential of --110 mV for the IC~50~ of HSTX-I on mNa~V~1.9 channel. Data are represented as mean ± SEM. **(E)** Effect of 3 μM HSTX-I on the conductance--voltage (G--V) relationship (right) and voltage dependence of steady-state inactivation (left) of rNa~V~1.8 channels. **(F)** HSTX-I (3 μM) shifted the G--V relationship of mNa~V~1.9 approximately 5 mV in a negative direction, but it did not induce a shift in steady-state inactivation. **(G)** Responses of a small DRG neuron to the sub-threshold (250--300 pA) and the threshold depolarizing current injections (350 pA). **(H)** Responses of a small DRG neuron treated with 3 μM HSTX-I to the sub-threshold (400--450 pA) and the threshold depolarizing current injections (500 pA). Arrows with numbers indicate the current amplitudes used to elicit the responses.](fphar-09-00186-g002){#F2}

Na~V~1.9 acts as a threshold channel that regulates excitability of DRG neurons to induce pain. Threshold depolarizing currents of small DRG neurons before and after application of HSTX- I (3 μM) were compared as illustrated in **Figures [2G,H](#F2){ref-type="fig"}**. Average current threshold of controls was 341.7 ± 15.37 pA (*n* = 6). After treatment with 3 μM HSTX-I, the current threshold was increased to 491.7 ± 27.13 pA (*n* = 6) which was significantly larger than that in the control (*P* = 0.0007). **Figure [2G](#F2){ref-type="fig"}** shows a small DRG neuron responding to subthreshold current injections (250--300 pA) and the threshold depolarizing current injections (350 pA) with graded membrane potential depolarizations before application of HSTX-I. After application of HSTX-I (3 μM), subthreshold current injections and threshold depolarizing current injections rose to 400--450 and 500 pA, respectively (**Figure [2H](#F2){ref-type="fig"}**).

Analgesic Functions of HSTX-I in Rodent Models
----------------------------------------------

Na~V~1.8/1.9 are preferentially expressed in nociceptors and have been showed to have a major role in pain ([@B39]; [@B12]). Given its inhibitory effects on Na~V~1.8/1.9, HSTX-I likely exerts analgesic functions. As illustrated in **Figure [3A](#F3){ref-type="fig"}**, HSTX-I reduced the response of pain in both the first (neurogenic pain, 0--5 min) and the second phases (inflammatory pain, 15--30 min) in formalin-induced paw licking mouse model, suggesting that HSTX-I has similar effect on both neurogenic and inflammatory pain. In the first phase, licking time was reduced 25.4% (*P* \< 0.01) and 36.5% (*P* \< 0.01) by 1.25 and 2.5 μmol/kg HSTX-I, while in the second phase, the licking time was reduced 9.8 and 24.6% (*P* \< 0.01), respectively. In the mouse model of abdominal writhing induced by acetic acid, 1.25 and 2.5 μmol/kg HSTX-I decreased writhing time by 15.5 and 28.8% (*P* \< 0.01), respectively (**Figure [3B](#F3){ref-type="fig"}**). Hot plate model of mouse showed that the latency of pain response was delayed by intraperitoneal administration of HSTX-I. The latency was delayed 10.7 and 29% (*P* \< 0.05) by 1.25 and 2.5 μmol/kg HSTX-I, respectively (**Figure [3C](#F3){ref-type="fig"}**). HSTX-I showed outstanding analgesic functions in several mouse models.

![Analgesic activities of HSTX-I in rodent models. The analgesic activities of HSTX-I in mouse models of formalin-induced paw licking **(A)**, abdominal writhing induced by acetic acid **(B)** and hot plate test **(C)**, respectively. Data are represented as mean ± SEM, *n* = 6. HSTX-I and morphine were administrated by intraperitoneal injection. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 are significantly different compared with the control (0.9% saline group).](fphar-09-00186-g003){#F3}

Discussion
==========

Voltage-gated sodium channels are integral transmembrane proteins that play a key role for the rapid depolarization of excitable cells ([@B17]). Their importance to pain perception is indisputable ([@B4]). Activation of TTX-R sodium channels, especially Na~V~1.8, contributes to action potential electrogenesis in neurons ([@B1]; [@B24]). Na~V~1.8 carries the majority of the current underlying the upstroke of the action potential in nociceptive neurons ([@B2]; [@B33]). Recent genetic and functional findings indicate that Na~V~1.9 is linked to human pain disorder ([@B10]). In order to successfully get blood meals and to anesthetize hosts, leeches possibly utilize salivary compounds acting on TTX-R sodium channels to inhibit activation of nociceptive neurons and overcome pain. Clinical experiments strongly indicate that leech therapy produces a strong and long lasting pain-reducing effect although no specific analgesic substance has been found.

The small peptide HSTX-I (ACKEYWECGAFLFCIEGICVPMI), which contains high density of half-cysteines as neurotoxins acting on ion channels, was identified and characterized from the leech salivary glands of *H. sylvestris* (**Figure [1](#F1){ref-type="fig"}**). It inhibited TTX-R Na^+^ channel currents and had no effect on voltage-gated Ca^2+^, K^+^, and TTX-S Na^+^ currents (Supplementary Figure [3](#SM1){ref-type="supplementary-material"}). HSTX-I reduced Na~V~1.8/1.9 currents but only shifted steady-state activation of Na~V~1.9 to hyperpolarization (**Figure [2F](#F2){ref-type="fig"}**). This finding indicated the effects of HSXT-I on Na~V~1.8 and Na~V~1.9 were slightly different. HSTX-I may interact with different domains of Na~V~1.8 and Na~V~1.9. Further mutations experiments may give an answer. Due to its selective activity on Na~V~1.8 and Na~V~1.9, HSTX-I could be a valuable tool for the study of Na~V~1.8 and Na~V~1.9.

It is noted that Na~V~1.8 is cold resistant, meaning that it is essential for pain and in maintaining the excitability of nociceptors at low temperatures ([@B33]). HSTX-I possibly blocks excitability of host nociceptors at low temperatures, such as water environment where leeches' generally inhabit. HSTX-I showed outstanding analgesic activity in several mouse models (**Figure [3](#F3){ref-type="fig"}**). It reduced the response of pain at both first (neurogenic pain, 0--5 min) and second phase (inflammatory pain, 15--30 min) with similar efficiency, suggesting that HSTX-I has similar effect on both neurogenic and inflammatory pain (**Figure [3A](#F3){ref-type="fig"}**). Na~V~1.8/1.9 may be safe targets for treatment of chronic pain because knocking out Na~V~1.8 or Na~V~1.9 in mice showed little adverse effects. HSTX-I selectively acted on Na~V~1.8/1.9 and showed significant analgesic effects in animal models, indicating it may be a promising lead molecule for development of analgesics.

Conclusion
==========

A novel peptide HSTX-I from *H. sylvestris* inhibited sodium channels (Na~V~1.8 and Na~V~1.9) and exerted direct analgesic function. The discovery of analgesic peptide HSTX-I in the leech riches our understanding of the molecular mechanisms of feeding strategies for hematophagia leeches. In addition, the current work is historically relevant because it reveals the specific analgesic substance and their pharmacological mechanisms in leech therapies.
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